ResMed posted robust revenue and earnings growth but faces operational cost pressure due to rising expenses.

ResMed operates two reporting units, historically named Sleep and Respiratory Care and SaaS. In alignment with the 2030 ...

Hello, and welcome to the Q1 Fiscal Year 2025 ResMed Earnings Conference Call ... which is the only area, right? So we've been ongoing competition with them in masks the whole time and they ...

Needham analyst Michael Matson maintained a Hold rating on Resmed (RMD – Research Report) today. The company’s shares closed ...

Adjusted net income increased by 35% to $325 million. William Blair sees ResMed well-positioned to capitalize on enduring sleep health trends. The company reported sales of $1.224 billion ...

Investors seek growth stocks to capitalize on above-average growth in financials that help these securities grab the market's attention and produce exceptional returns. But finding a great growth ...

Oppenheimer analyst Suraj Kalia maintained a Hold rating on Resmed (RMD – Research Report) today. The company’s shares closed ...

ResMed Inc.’s RMD robust performance of its Mask business is supported by continued product development within the portfolio. Its Software-as-a-Service (SaaS) business continues to benefit from ...

Pre-earnings options volume in ResMed (RMD) is 3.5x normal with puts leading calls 7:5. Implied volatility suggests the market is anticipating a move near 6.9%, or $16.63, after results are released.